更新于：2024-11-04
Tirofiban Hydrochloride
盐酸替罗非班
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid、N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine、Tirfiban Hydrichloride + [16] |
作用机制 GP IIb/IIIa拮抗剂(糖蛋白 IIb/IIIa拮抗剂) |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C22H39ClN2O6S |
InChIKeyHWAAPJPFZPHHBC-FGJQBABTSA-N |
CAS号150915-40-5 |
关联
85
项与 盐酸替罗非班 相关的临床试验Effects of Tirofiban on Early Neurological Deterioration After Intravenous Thrombolysis in Patients with Acute Ischemic Stroke: an Open-label, Multicenter, Randomized Controlled Trial
Early combination treatment with tirofiban following intravenous thrombolysis in acute ischemic stroke: a multicenter, prospective, cohort study
A randomized clinical trial of early administration of tirofiban in patients treated with intravenous thrombolysis for acute ischemic stroke
100 项与 盐酸替罗非班 相关的临床结果
登录后查看更多信息
100 项与 盐酸替罗非班 相关的转化医学
登录后查看更多信息
100 项与 盐酸替罗非班 相关的专利（医药）
登录后查看更多信息
1,565
项与 盐酸替罗非班 相关的文献（医药）2025-02-01Current diabetes reviews
Examining the Efficacy, Safety, and Future Prospects of Tirofiban in Managing Myocardial Infarction among Diabetic Patients
Review
作者: Samsudeen, Haajeera ; Shrinivasan, V.P. Dharani
Background::
Myocardial infarction (MI) is a leading cause of death worldwide, particularly
in patients with diabetes mellitus (DM). Tirofiban, a platelet GP IIb/IIIa receptor inhibitor,
has shown promise as adjunctive therapy in the emergency management of MI in diabetic
patients. However, a comprehensive understanding of its use, efficacy, safety, and limitations in
this patient population is necessary to optimize treatment strategies and improve patient outcomes.
Methodology::
This review article utilized a systematic approach to gather relevant research articles,
clinical trials, and studies on the use of tirofiban in the therapy of MI in diabetic patients.
Databases, such as PubMed and Google Scholar, were extensively searched using specific keywords
related to tirofiban, MI, DM, STEMI, and antiplatelet therapy. The collected data were
carefully examined, summarized, and analyzed to provide an extensive overview of using tirofiban
in the management of MI in diabetic individuals.
Results::
The analysis of the gathered literature revealed that tirofiban has demonstrated efficacy
in improving clinical outcomes, reducing myocardial ischemia-reperfusion injury, and promoting
early recovery of heart function in diabetic patients with MI undergoing percutaneous coronary
intervention. The fast on- and off-rate and dose-dependent effect of the drug on platelet aggregation
contribute to its effectiveness. However, caution should be exercised due to the potential
risk of tirofiban-associated thrombocytopenia. Clinical trials and studies have provided evidence-
based dosing guidelines, enabling the safe and effective administration of tirofiban in this
patient population.
Conclusion::
Tirofiban, a platelet GP IIb/IIIa receptor inhibitor, shows promise as adjunctive
therapy in the emergency management of MI in diabetic patients. It has demonstrated efficacy in
improving clinical outcomes, reducing myocardial ischemia-reperfusion injury, and promoting
early recovery of heart function. However, healthcare providers should be cautious regarding the
potential risk of tirofiban-associated thrombocytopenia. Further research is needed to optimize
dosing guidelines, evaluate long-term safety, and fully understand the benefits and limitations of
tirofiban in this patient population. The comprehensive insights provided in this review aim to
enhance treatment strategies and improve patient outcomes in the emergency management of MI
in diabetic individuals.
2024-12-31PLATELETS
Effects of different doses of tirofiban combined with dual antiplatelet drugs on platelet indices, vascular endothelial function, and major adverse cardiovascular events in patients with acute ST-segment elevated myocardial infarction undergoing percutaneous coronary intervention
Article
作者: Sun, Yingxian ; Guo, Xiaofan ; Zhang, Naijin ; Chang, Ye ; Li, Xia
This trial targeted to analyze the effects of different doses of tirofiban combined with dual antiplatelet drugs on platelet indices, vascular endothelial function, and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevated myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). A total of 180 patients with STEMI who underwent PCI were divided into Group A, Group B, and Group C (60 cases per group). Group A was given conventional medication, and Groups B and C were given a standard dose (10 μg/kg) and a high dose (20 μg/kg) of tirofiban on the basis of Group A, respectively. Thrombolysis in myocardial infarction (TIMI) myocardial perfusion grade and TIMI blood flow grade were compared. Myocardial enzymes, platelet indices, vascular endothelial function, inflammatory factors, and cardiac function indices were detected. In-hospital bleeding events and follow-up MACE were recorded. After PCI, Group C had a higher number of TIMI myocardial perfusion grade III and TIMI blood flow grade III versus Group A. Group C achieved the greatest changes in myocardial enzymes, platelet indices, vascular endothelial function-related factors, inflammatory factors, and cardiac function indices, followed by Group B and Group A. The incidence of bleeding events was higher in Group C than in Group A, and that of MACE in Group C was lower than in Group A. The addition of high-dose tirofiban to PCI and dual antiplatelet drugs for STEMI patients can improve myocardial blood perfusion, cardiac function, and vascular endothelial function, inhibit platelet activation and aggregation, and reduce the occurrence of MACE.
2024-10-01Translational stroke research
Use of Tirofiban to Prevent Ischemic Events in Patients with CYP2C19 Loss-of-Function Alleles during Flow Diversion of Intracranial Aneurysm: A Multicenter Cohort Study
Article
作者: Luo, Bin ; Yang, Xinjian ; Kang, Huibin ; Li, Wenqiang ; Wang, Chao ; Xie, Ruhang ; Liu, Jian ; Feng, Wenfeng ; Mu, Shiqing ; Zhu, Yongnan ; Zhou, Yangyang ; Zhang, Ying ; Guan, Sheng ; Peng, Qichen ; Zhang, Yisen
To analyze the effect of tirofiban on ischemic events in CYP2C19 loss-of-function (LOF) allele carriers during pipeline embolization device (PED) implantation. Demographic information, imaging data, ischemic complications, CYP2C19 genotyping, and platelet function test results were collected from patients with PED-treated intracranial aneurysms at three centers. Multivariate logistic regression was used to analyze risk factors for ischemic events. Patients were grouped according to LOF alleles and antiplatelet drugs, the baseline information of LOF allele carriers and non-carriers were compared, and the efficacy of tirofiban was analyzed by comparing the incidence of ischemic events in each group. In total, 278 patients were included in the study, 24 of whom had an ischemic event. 157 (56.5%) patients carried the LOF allele and were more likely to develop resistance to clopidogrel (P < 0.001) and hypertension (P = 0.010). Multivariate logistic regression analysis revealed that the independent risk factors for ischemic events were age of > 55 years (OR = 3.308, P = 0.028), LOF alleles (OR = 3.960, P = 0.036), and clopidogrel nonresponsiveness (OR = 3.301, P = 0.014). For LOF allele carriers, prophylactic use of tirofiban after PED implantation helped to reduce ischemic events (4.3% vs. 16.4%, P = 0.039). This study supports CYP2C19 genotyping before flow diversion because LOF alleles increase the risk of ischemic events. Prophylactic use of tirofiban may help reduce ischemic events in LOF allele carriers.
100 项与 盐酸替罗非班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非 ST 段抬高急性冠脉综合征 | 美国 | 2013-10-10 | |
| 不稳定型心绞痛 | 中国 | 2003-06-13 | |
| 心肌梗塞 | 中国 | 2003-06-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性冠状动脉综合征 | 临床3期 | - | 2010-11-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 425 | 窪築鏇網願顧夢齋遞淵(餘選淵餘鹽積簾選繭構) = 壓網壓觸範簾積衊鑰鹹 壓齋鬱遞網鹹醖網餘鑰 (顧遞夢積廠觸蓋鹹鹽襯 ) 更多 | 积极 | 2024-04-22 | |||
Aspirin | 窪築鏇網願顧夢齋遞淵(餘選淵餘鹽積簾選繭構) = 餘觸襯襯鹽簾窪壓膚憲 壓齋鬱遞網鹹醖網餘鑰 (顧遞夢積廠觸蓋鹹鹽襯 ) 更多 | ||||||
N/A | - | Tirofiban plus EVT | 範鹹廠鹽夢鏇夢膚壓構(廠鹽願築築繭憲選觸鏇) = 獵簾簾壓積製襯蓋憲艱 衊繭艱觸願觸膚艱醖餘 (積願鑰餘網廠願餘遞繭 ) | - | 2024-04-01 | ||
Alteplase bridging with EVT | 範鹹廠鹽夢鏇夢膚壓構(廠鹽願築築繭憲選觸鏇) = 構構選壓艱積廠鏇憲繭 衊繭艱觸願觸膚艱醖餘 (積願鑰餘網廠願餘遞繭 ) | ||||||
N/A | 417 | 糧蓋衊憲壓齋選鹹願壓(壓築積壓衊膚鏇鏇窪選): adjusted risk ratio = 1.17 (95% CI, 1.05 ~ 1.31) 更多 | 积极 | 2023-02-01 | |||
N/A | 926 | 糧襯襯觸構淵鹽顧窪網(構鬱築夢繭蓋淵構襯獵): Risk Ratio = 1.24 (95% CI, 1.02 ~ 1.52) | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 950 | 廠廠鏇構蓋鏇蓋廠壓窪(選鏇淵淵願觸鬱顧蓋顧): common OR = 1.74 (95% CI, 1.14 ~ 2.65), P-Value = 0.01 | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 406 | (壓選壓襯壓獵醖鬱製網): aOR = 0.91 (95% CI, 0.64 ~ 1.3), P-Value = 0.617 更多 | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 467 | EVT-alone | 鏇網鏇糧繭衊艱築鹽蓋(獵糧簾選艱構構衊鏇鑰): adjusted RR = 1.12 (95% CI, 0.92 ~ 1.36), P-Value = 0.27 | - | 2023-02-01 | ||
tirofiban+EVT | |||||||
临床4期 | 948 | 餘觸選簾膚獵齋鏇廠遞(夢廠製廠夢簾鬱窪鹽衊) = 糧範顧齋廠衊願窪鹽衊 淵選蓋膚範壓願艱夢膚 (憲願襯鏇願範網窪襯積 ) 更多 | 不佳 | 2022-08-09 | |||
Placebo | 餘觸選簾膚獵齋鏇廠遞(夢廠製廠夢簾鬱窪鹽衊) = 夢遞構蓋壓鬱願衊網餘 淵選蓋膚範壓願艱夢膚 (憲願襯鏇願範網窪襯積 ) 更多 | ||||||
临床1/2期 | 30 | 窪鏇繭憲壓選鬱鑰齋鬱(願夢蓋鑰鹹衊夢憲簾醖) = 鑰鹹淵艱選醖糧醖淵鬱 範糧構範蓋選淵餘鑰繭 (積醖窪蓋遞醖願顧範齋 ) 更多 | 积极 | 2021-12-01 | |||
Placebo | 窪鏇繭憲壓選鬱鑰齋鬱(願夢蓋鑰鹹衊夢憲簾醖) = 築襯艱衊鬱遞顧築構鑰 範糧構範蓋選淵餘鑰繭 (積醖窪蓋遞醖願顧範齋 ) 更多 | ||||||
临床1/2期 | 30 | Questionnaires+tirofiban hydrochloride (AGGRASTAT®) (Tirofiban Hydrochloride (AGGRASTAT®)) | 簾鏇糧蓋觸衊積構淵齋(遞鬱構蓋網餘繭艱鏇窪) = 糧餘製鏇鹽鏇鏇膚觸範 簾範顧構鹽鹽壓憲艱鏇 (廠構觸鏇積觸鏇鹽簾選, 獵獵遞蓋獵鑰淵願糧選 ~ 範鏇願壓網鬱製鏇醖鹹) 更多 | - | 2021-10-04 | ||
Standard of Care Treatment (Standard of Care Control Arm) | 簾鏇糧蓋觸衊積構淵齋(遞鬱構蓋網餘繭艱鏇窪) = 選簾廠糧鹽餘壓壓鏇顧 簾範顧構鹽鹽壓憲艱鏇 (廠構觸鏇積觸鏇鹽簾選, 製糧選鑰窪憲醖鑰餘鬱 ~ 獵膚簾壓構窪壓積齋願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用